The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

ABSTRACT: When identified at early stages, most well-differentiated thyroid cancers are readily treated and yield excellent outcomes. Follicular thyroid cancer (FTC) however, when diagnosed at a late stage, may be very resistant to treatment, and exhibits 10-year survival rates less than 40%. Despite substantial progress in recent years, we still have limited understanding of the molecular and biological interrelationships between the various subtypes of benign and malignant follicular thyroid neoplasms. In contrast to the wealth of information available regarding papillary thyroid carcinoma (PTC), the triggering mechanisms of FTC development and the major underlying genetic alterations leading to follicular thyroid carcinogenesis remain obscure. Recent studies have focused on a chromosomal transloc

SUBMITTER: Eberhardt NL 

PROVIDER: S-EPMC2849860 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature